This hypothesis proposes that selective activation of LXRα (NR1H3) represents a superior therapeutic approach for addressing dyslipidemia by targeting hepatic cholesterol homeostasis rather than microglial cholesterol accumulation. LXRα, predominantly expressed in metabolically active tissues including liver, intestine, and kidney, serves as the primary regulator of whole-body cholesterol efflux and lipid metabolism. Selective LXRα agonism would enhance hepatic APOE production and secretion, inc
CYP2J2/ω-3 DHA epoxides (sEH inhibition) · lipidomics · -
Composite 0.752
Price $0.63
Evidence For 0
Evidence Against 0
The hypothesis proposes that ω-3 docosahexaenoic acid (DHA) is metabolized by CYP2J2 to generate protective epoxides that shield synaptic membranes from amyloid-beta (Aβ)-induced rigidification. Evidence from planar lipid bilayer experiments demonstrates that CYP2J2-derived epoxides mitigate Aβ-induced membrane rigidity (pmid:31243156). Aβ oligomers are known to increase membrane cholesterol content by approximately 40% and expand raft domain size in cortical neurons (pmid:24503041). Supporting
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Lipid MetabolismUnspecified Mechanismlipidomics
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
LXRα-Selective Agonism to Enhance Hepati
11/11
dimensions won
ω-3 Docosahexaenoic Acid (DHA) Epoxide G
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.75
0.80
Evidence
0.34
0.75
Novelty
0.00
0.60
Feasibility
0.00
0.75
Impact
0.00
0.80
Druggability
0.75
0.80
Safety
0.50
0.70
Competition
0.55
0.55
Data
0.70
0.75
Reproducible
0.70
0.75
KG Connect
0.50
0.50
Score Breakdown
Dimension
LXRα-Selective Agonism to Enha
ω-3 Docosahexaenoic Acid (DHA)
Mechanistic
0.750
0.800
Evidence
0.345
0.750
Novelty
0.000
0.600
Feasibility
0.000
0.750
Impact
0.000
0.800
Druggability
0.750
0.800
Safety
0.500
0.700
Competition
0.550
0.550
Data
0.700
0.750
Reproducible
0.700
0.750
KG Connect
0.500
0.500
Evidence
LXRα-Selective Agonism to Enhance Hepatic APOE Secretion and
No evidence citations yet
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2
No evidence citations yet
Debate Excerpts
LXRα-Selective Agonism to Enhance Hepatic APOE Sec
4 rounds · quality: 0.50
Theorist
# Novel Therapeutic Hypotheses: Lipid Metabolism Dysregulation in Alzheimer's Disease
---
## Hypothesis 1: CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and R...
Skeptic
# Critical Evaluation of Lipid Metabolism Hypotheses in Alzheimer's Disease
## Hypothesis 1: CYP46A1 Activation
### Weaknesses in Evidence
The hypothesis presents a linear model of cholesterol ef...
Domain Expert
# Drug Development Assessment: Lipid Metabolism Hypotheses in Alzheimer's Disease
## Executive Summary
The seven hypotheses span a spectrum of druggability—from well-established nuclear receptor a...
# Novel Therapeutic Hypotheses: Lipid Metabolism Dysregulation in Alzheimer's Disease
---
## Hypothesis 1: CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and R...
Skeptic
# Critical Evaluation of Lipid Metabolism Hypotheses in Alzheimer's Disease
## Hypothesis 1: CYP46A1 Activation
### Weaknesses in Evidence
The hypothesis presents a linear model of cholesterol ef...
Domain Expert
# Drug Development Assessment: Lipid Metabolism Hypotheses in Alzheimer's Disease
## Executive Summary
The seven hypotheses span a spectrum of druggability—from well-established nuclear receptor a...